Provider: ValuEngine, Inc.
Revive Therapeutics Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Revive Therapeutics Ltd announces positive pre-clinical results for Rett Syndrome
Revive Therapeutics Ltd:Says positive results from a pre-clinical study with tianeptine for the treatment of Rett syndrome, a rare disease (referred to by Revive as 'REV-003').
Latest Developments forRevive Therapeutics Ltd
- Revive Therapeutics announces positive study results from its research collaboration with Rettsyndrome.org
- Revive Therapeutics Ltd completes prospectus offering of about C$3,000,000
- Revive Therapeutics Ltd submits IND application to US FDA for the clinical development of Bucillamine for the treatment of Gout
- Revive Therapeutics Ltd announces positive results of REV-001 Phase 2A proof-of-concept study
Latest Key Developments inHolding
- Melrose Industries PLC enters agreement for disposal of Elster to Honeywell
- Sintesi Societa di Investimenti e Partecipazioni SpA shareholders decide not to proceed with dissolution and liquidation of company
- First Mining Finance Corp commence trading on OTCQB
- China Financial Leasing Group Ltd gives H1 2015 profit outlook
- Share this
- Digg this